Development of immunotherapy for the treatment of malignancies refractory to conventional therapies

Cytokines and Molecular Therapy

Volumn 2, Issue 1, 1996, Pages 13-19

  Kirn, Sue ^a   Haas, Gabriel P ^a   Hillman, Gilda G ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Gene therapy; Immunotherapy

Indexed keywords

CYTOKINE; INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER; CANCER IMMUNOTHERAPY; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADOPTIVE TRANSFER; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM METASTASIS; NEOPLASMS; TRANSFECTION;

EID: 0029865934     PISSN: 13556568     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Hillman GG, Haas GP, Wahl WH, Callewaert DM, Adoptive immunotherapy of cancer: biological response modifiers and cytotoxic cell therapy. Biotherapy (1992) 5: 119-29.
2. Rosenberg SA, Adoptive cellular therapy in patients with advanced cancer: an update. Biologic Therapy of Cancer Updates (1991) 1: 1-15.
3. Herberman RB, Ortaldo JR, Bonnard GD, Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature (1979) 277: 221-3.
4. Quesada JR, Rios A, Swanson D et al, Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol (1985) 3: 1522-8.
5. Haas GP, Hillman GG, Redman BG, Pontes JE, Immunotherapy of renal cell carcinoma. CA Cancer J Clin (1993) 43: 177-87.
6. Morgan DA, Ruscetti FW, Gallo R, Selective in vitro growth of T lymphocytes form natural human bone marrows. Science (1976) 193: 10007-8.
7. Smith KA, Interleukin 2: inception, impact, and implications. Science (1988) 240: 1169-76.
8. Foon RA, Biological response modifiers: the new immunotherapy. Cancer Res (1989) 49: 1621-39.
9. Trinchieri G, Matsumoto-Kobayshi M, Clark SC et al, Response of resting peripheral blood natural killer cells to interleukin 2. J Exp Med (1984) 160: 1147-69.
10. Rosenstein M, Yron I, Kaufman Y, Rosenberg SA, Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2. Cancer Res (1984) 44: 1946-53.
11. Rosenberg SA, Mule JJ, Spiess PJ et al, Regression of established pulmonary métastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 161: 1169-88.
12. Ettinghausen SE, Rosenberg SA, Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res (1986) 46: 2784-92.
13. Lotze MT, Chang AE, Scipp ÇA et al, High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatmentrelated morbidity, and histologie findings. J Am Med Assoc( 1986) 256: 3117-24
14. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med (1987) 316: 889-905.
15. Sondel PM, Kohler PC, Hank JA et al, Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res (1988) 48: 2561-7.
16. Sosman JA, Kohler PC, Hank JA et al, Repetitive weekly cycles of interleukin-2. II. Clinical and immunologie effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst (1988) 80: 1451-61.
17. Rosenberg SA, Lotze MT, Yang JC et al, Experience with the use of high-dose interleukin-2 in the treatment of 652 patients with cancer. Ann Surg (1989) 210: 474-85.
18. Rosenberg SA, Lotze MT, Yang JC et al, Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 85: 622-32.
19. Spencer WF, Linhan WM, Walther MM et al, Immunotherapy with interleukin-2 and a-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol (1992) 147: 24-30.
20. Belldegrun A, Figlin R, Haas GP, deKernion JB, Immunotherapy for metastatic renal cell carcinoma. World J Urol (1991} 9: 157-9.
21. Shu SY, Chou T, Sakai K, Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity. J Immimol (1989) 143: 740-8.
22. Yoshizawa H, Chang AE, Shu S, Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol (1991) 147: 729-37.
23. Chang AE, Yoshizawa H, Sakai K et al, Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res (1993) 53: 1043-50.
24. Siegel JP, Puri RK, Interleukin-2 toxicity. J Clin Oncol(1991)9: 694-704.
25. Cameron RB, Mclntosh JK, Rosenberg SA, Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic métastases. Cancer Res (1988) 48: 5810-17.
26. Brunda MJ, Bellantoni D, Sulich V, In vivo antitumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with induction of cytotoxic cells resembling natural killer cells. Intjf Cancer (1987) 40: 365-71.
27. Truitt GA, Stern LL, Bontempo J, Recombinant human interleukin-2 alone and in combination with interferon alpha, is a potent anti-tumor agent against colon 38 and Lewis lung carcinoma in mice. Proc AnnuAmAssoc Cancer Res (1987) 28: 1463A.
28. Mclntosh JK, Mule JJ, Merino MJ et al, Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Res (1988) 48: 4011-7.
29. Kawase I, Komuta K, Hara H et al, Combined therapy of mice bearing a lymphokine-activated killerresistant tumor with recombinant interleukin-2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Cancer Res (1988)48: 1173-9.
30. Hank JA, Albertini M, Wesly OH et al, Clinical and immunological effects of treatment with murine antiCD3 monoclonal antibody along with interleukin 2 in patients with cancer. Clin Cancer Res (1995) 1: 481-91.
31. Rosenberg SA, Spiess P, Lafreniere R, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 223: 1318-21.
32. Cameron RB, Spiess PJ, Rosenberg SA, Synergistic antitumor activity of tumor infiltrating lymphocytes, interleukin-2, and local tumor irradiation: studies on the mechanism of action, jf Exp Med (1990) 171: 249-63.
33. Rosenberg SA, Packard BS, Aebersold PM et al, Immunotherapy of patients with metastatic melanoma using tumor infiltrating lymphocytes and interleukin2: preliminary report. N Engl J Med (1988) 319: 1676-80.
34. Rosenberg SA, Yannelli JR, Yang JC et al, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2. J Natl Cancer Inst (1994) 86: 1159-66.
35. Fujita K, Ikarishi H, Takakuwa K et al, Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumorinfiltrating lymphocytes. Clin Cancer Res (1995) 1: 501-7.
36. Kradin RL, Kurnick JT, Lazarus DS et al, Tumor infiltrating lymphocytes and interleukin-2 in treat-ment of advanced cancer. Lancet (1989) i: 57780.
37. Bukowski RM, Sharfman W, Murthy S et al, Clinical results and characterization of tumor infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res (1991) 51: 4199-4205.
38. Belldegrun A, Pierce W, Kaboo R et al, Interferon alpha-primed tumor infiltrating lymphocytes combined with interleukin 2 and interferon-alpha as a therapy for metastatic renal cell carcinoma. J Urol (1993) 150: 1384-1390.
39. Hillman GG, Sud S, Dybal EJ et al, Combinaüons of lymphocyte activating agents for expansion of tumor infiltrating lymphocytes from renal cell carcinoma. In: Combination therapies: biological response modifiers in the treatment of cancer and infections diseases (ed AL Goldstein, E Garaci) 39-48. Plenum Press, New York, 1992.
40. Kawakami Y, Rosenberg SA, Lotze MT, Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J ExpMed(1998) 168: 2183-91.
41. Pfizenmaier K, Scheurich P, Schluter C, Kronke M, Tumor necrosis factor enhances HLA-A,B,C and HLA-DR gene expression in human tumor cells. J Immunol (1987) 138: 975-80.
42. Yi Li W, Lucsheng S, Kanbour A et al, Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin-2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes. Cancer Res (1989) 49: 5979-85.
43. Finke JH, Rayman P, Alexander J et al, Characterizatin of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma. Cancer Res (1990) 50: 2363-70.
44. Wong JT, Pinto CE, Gifford JD et al, Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies. J Immunol (1989) 143: 3404-11.
45. Pockaj B A, Sherry RM, Wei JP et al, Localization of 11'indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer (1994) 73: 1731-7.
46. Kasid A, Morecki S, Aebersold P et al, Human gene transfer: characterization of human tumor infiltrating lymphocytes as vehicles for retroviral mediated gene transfer in man. Proc NatlAcad Sci USA (1990) 87: 473-7.
47. Rosenberg SA, Aebersold P, Cornetta K et al, Gene transfer into humans: immunotherapy of patients with advanced melanoma using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl JMf(1990) 323:570-8.
48. Rosenberg SA, Immunotherapy and gene therapy of cancer. Cancer Res (1991) 51s: 5074s-9s.
49. Lange JR, Raubitschek AA, Pockaj BA et al, A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy. J Immunotherapy (1992) 12: 265-71.
50. Dybal EJ, Haas GP, Maughan RL et al, Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. J Urol (1992) 148: 1331-7.
51. Chakrabarty A, Hillman GG, Maughan RL et al, Immunotherapy and radiation therapy combined for the treatment of murine renal carcinoma. Surgical Forum XLJII (1992) 43: 758-60.
52. Chakrabarty A, Hillman GG, Maughan RL et al, Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary métastases in a murine renal adenocarcinoma model. In Vivo (1994) 8: 25-32.
53. Younes E, Haas GP, Dezso B et al, Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol (1995) 165: 243-51.
54. Hrushesky WJ, Murphy GP, Investigation of a new renal tumor model. J Surg Res (1973) 15: 327-32.
55. Hillman GG, Droz JP, Haas GP, Experimental animal models for the study of therapeutic approaches in renal cell carcinoma. In Vivo (1994) 8: 77-80.
56. Lam JS, Hillman GG, Younes E et al, Effect of local tumor irradiation and interleukin-2 therapy in different murine tumors. J Immunother (1995) 18: 28-34.
57. Younes E, Haas GP, Dezso B et al, Radiationinduced effects on murine kidney tumor cells: role in the interaction of local irradiation and immunotherapy. J Urol (1995) 153: 2029-33.
58. Gregorian SK, Battisto JR, Immunosuppression in murine renal cell carcinoma: I. Characterization of extent, severity and sources. Cancer Immunol Immunother (1990) 31: 325-34.
59. Gregorian SK, Battisto JR, Immunosuppression in murine renal cell carcinoma: II. Identification of responsible lymphoid cell phenotypes and examina-tion of elimination of suppression. Cancer Immunol Immimother (1990) 31: 335-41.
60. Mizoguchi H, O'Shea JJ, Longo DL et al, Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (1992) 258: 1795-8.
61. Fearon ER, Pardoll DM, Itaya T et al, Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell (1990) 60: 397-403.
62. Gansbacher B, Bannerji R, Daniels B et al, Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity, jf Exp Med (1990) 172: 1217-24.
63. Gansbacher B, Bannerji R, Daniels B et al, Retroviral vector-mediated -y-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res (1990) 50: 7820-5.
64. Asher AL, Mule JJ, Kasid A et al, Murine tumor cells transduced with the gene for tumor necrosis factor- Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol (1991) 146: 3227-34.
65. Colombo MP, Ferrari G, Stoppacciaro A et al, Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med (1991) 173: 889-97.
66. Saito S, Bannerji R, Gansbacher B et al, Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res (1994) 54: 3516-20.
67. Weber JS, Rosenberg SA, Effects of murine tumor MHC class I expression on the anti-tumor activity of tumor infiltrating lymphocytes. J Natl Cancer Inst (1990) 82: 755-61.
68. Nabel GJ, Nabel EG, Yang ZY et al, Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA (1993) 90:11307-11.